A detailed history of Newbridge Financial Services Group, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 3,084 shares of TGTX stock, worth $82,959. This represents 0.02% of its overall portfolio holdings.

Number of Shares
3,084
Previous 3,662 15.78%
Holding current value
$82,959
Previous $55,000 1.82%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Sep 11, 2024

SELL
$13.32 - $19.19 $7,698 - $11,091
-578 Reduced 15.78%
3,084 $54,000
Q1 2024

Apr 24, 2024

SELL
$13.02 - $21.3 $14,973 - $24,495
-1,150 Reduced 23.9%
3,662 $55,000
Q4 2023

Mar 28, 2024

SELL
$6.68 - $18.81 $2,979 - $8,389
-446 Reduced 8.48%
4,812 $82,000
Q3 2023

Oct 17, 2023

BUY
$8.36 - $26.5 $10,968 - $34,768
1,312 Added 33.25%
5,258 $43,000
Q2 2023

Jul 21, 2023

SELL
$15.48 - $35.0 $7,740 - $17,500
-500 Reduced 11.25%
3,946 $98,000
Q1 2023

Apr 18, 2023

BUY
$10.23 - $19.34 $1,780 - $3,365
174 Added 4.07%
4,446 $66,000
Q4 2022

Jan 17, 2023

SELL
$5.01 - $11.83 $6,823 - $16,112
-1,362 Reduced 24.17%
4,272 $0
Q3 2022

Oct 13, 2022

BUY
$4.57 - $8.4 $4,396 - $8,080
962 Added 20.59%
5,634 $33,000
Q2 2022

Jul 15, 2022

SELL
$3.74 - $10.66 $1,421 - $4,050
-380 Reduced 7.52%
4,672 $20,000
Q4 2021

Jan 19, 2022

SELL
$15.2 - $35.51 $2,918 - $6,817
-192 Reduced 3.66%
5,052 $96,000
Q3 2021

Oct 27, 2021

SELL
$21.78 - $40.45 $8,232 - $15,290
-378 Reduced 6.72%
5,244 $175,000
Q2 2021

Sep 07, 2021

SELL
$32.5 - $48.96 $6,272 - $9,449
-193 Reduced 3.32%
5,622 $218,000
Q1 2021

Sep 07, 2021

BUY
$41.61 - $54.3 $220,782 - $288,115
5,306 Added 1042.44%
5,815 $280,000
Q4 2020

Sep 07, 2021

BUY
$25.27 - $54.9 $12,862 - $27,944
509 New
509 $26,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.91B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.